

Clinical Criteria

Subject:	Tegsedi (inotersen)		
Document #:	ING-CC-0084	Publish Date:	04/01/2019 09/23/2019
Status:	New Revised	Last Review Date:	10/09/2018 08/16/2019

Table of Contents

Overview	Coding	References
Clinical criteria	Document history	

Overview

This document addresses the use of Tegsedi (inotersen), an antisense oligonucleotide approved by the Food and Drug Administration (FDA) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. hATTR amyloidosis was formerly known as familial amyloid polyneuropathy (FAP).

Hereditary transthyretin (hATTR) amyloidosis is a multisystemic, progressive, life-threatening disease characterized by extracellular deposition of amyloid fibrils composed of misfolded transthyretin (TTR), a plasma transport protein produced predominantly by the liver. Amyloid fibrils accumulate in various organs and tissues such as the heart, kidney, gastrointestinal tract, and peripheral nerves, resulting in clinical manifestations such as polyneuropathy and cardiomyopathy. Potential symptoms associated with hATTR amyloidosis include but are not limited to muscle weakness, difficulty ambulating, impaired balance, orthostatic hypotension, disturbances in GI mobility, heart failure, arrhythmias and sudden death due to severe conduction disorders.

Due to the constellation of symptoms and multisystemic nature of the disease, various assessments need to be utilized in an effort to quantify the overall disease burden for each individual with hATTR amyloidosis. Examples of clinical tests include the Neuropathy Impairment Score (NIS) and Polyneuropathy Disability (PND) Score. Clinical trials evaluated the use of Tegsedi in individuals with hATTR amyloidosis and mild to moderate polyneuropathy. An example of mild to moderate polyneuropathy status is an individual who is able to ambulate with or without the use of assistance.

The efficacy of Tegsedi was demonstrated in a randomized, double-blind, placebo-controlled trial in 172 adults with stage 1 (ambulatory) or stage 2 (ambulatory with assistance) hereditary transthyretin amyloidosis with polyneuropathy. Study participants had a Neuropathy Impairment Score (NIS) of 10-130 (NIS scale ranges from 0-244), a TTR mutation confirmed by genotyping and amyloid deposits documented on biopsy. Key exclusion criteria were previous liver transplant, New York Heart Association (NYHA) class III or IV heart failure, severe renal impairment or end-stage renal disease, moderate or severe hepatic impairment and other causes of polyneuropathy unrelated to hATTR amyloidosis. Both primary efficacy assessments favored Tegsedi over placebo. The difference in least-squares mean change from baseline to week 66 between groups was -19.7 points (95% CI -26.4 to -13.0) for the standardized modified Neuropathy Impairment Score+7 (mNIS+7) composite score and -11.7 points (95% CI -18.3 to -5.1) for the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire.

Treatment with Tegsedi leads to a decrease in serum vitamin A levels. Individuals should be advised to take vitamin A supplementation at the recommended daily allowance while receiving Tegsedi therapy.

Tegsedi has black box warnings for thrombocytopenia and glomerulonephritis. Tegsedi causes reductions in platelet count that may result in sudden and unpredictable thrombocytopenia and is contraindicated in individuals with a platelet count below $100 \times 10^9/L$ at baseline. During treatment, platelet counts should be monitored weekly if values are $75 \times 10^9/L$ or greater and more frequently if values are less than $75 \times 10^9/L$. Following discontinuation of therapy, platelet counts should be monitored for 8 weeks or longer to verify values remain above $75 \times 10^9/L$. Tegsedi can cause glomerulonephritis that may require immunosuppressive treatment and may result in dialysis-dependent renal failure. Tegsedi should not be initiated in individuals with urinary protein to creatinine ratio (UPCR) of 1000 mg/g or higher. Serum creatinine, estimated glomerular filtration rate (eGFR) and UPCR should be monitored at baseline and every two weeks during treatment. Tegsedi should not be administered to individuals who develop a UPCR of 1000 mg/g or higher or eGFR below $45 \text{ mL/min/1.73 m}^2$, pending further evaluation. The FDA has required the manufacturer to develop a comprehensive risk

management program that includes the enrollment of prescribers in the Tegsedi Risk Evaluation and Mitigation Strategy (REMS) Program. Additional information and forms for individuals, prescribers and pharmacists may be found at www.tegsedirems.com.

Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Tegsedi (inotersen)

Requests for Tegsedi (inotersen) may be approved if the following criteria are met:

- I. Individual has a diagnosis of hereditary transthyretin (hATTR) amyloidosis or familial amyloid polyneuropathy (FAP); **AND**
- II. Individual has a TTR mutation confirmed by genotyping [\(Benson, 2018\)](#); **AND**
- III. Individual has associated mild to moderate polyneuropathy [\(Benson, 2018\)](#); **AND**
- IV. Individual has a baseline platelet count greater than or equal to $100 \times 10^9/L$; **AND**
- V. Individual has a urinary protein to creatinine ratio (UPCR) less than 1000 mg/g.

Requests for Tegsedi (inotersen) may not be approved for the following:

- ~~I.~~ **All other indications not included above; OR**
- ~~II.~~ Individual has a history of liver transplantation; **OR**
- ~~III.~~ Individual has severe renal impairment or end-stage renal disease; **OR**
- ~~IV.~~ Individual has a history of acute glomerulonephritis caused by Tegsedi ~~(inotersen)~~; **OR**
- ~~V.~~ Individual has moderate or severe hepatic impairment; **OR**
- ~~VI.~~ Individual has New York Heart Association (NYHA) class III or IV heart failure [\(Benson, 2018\)](#); **OR**
- ~~VII.~~ Individual has sensorimotor or autonomic neuropathy not related to hATTR amyloidosis (monoclonal gammopathy, autoimmune disease, etc.) [\(Benson, 2018\)](#); **OR**
- ~~VIII.~~ Individual is using in combination with Onpattro, Vyndaqel or Vyndamax.

Formatted: Font: Bold

Formatted: Font: Bold

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

C9399	Unclassified drugs or biologicals (Hospital Outpatient Use ONLY) [Tegsedi] (Delete 10/1/19)
J3490	Unclassified drugs [Tegsedi] (Delete 10/1/19)
J0222	Injection, Patisiran, 0.1 mg [Tegsedi] (Effective 10/1/19)

ICD-10 Diagnosis

E85.1-E85.9	Neuropathic hereditary amyloidosis
G62.9	Polyneuropathy, Unspecified

Document History

Revised: 08/16/2019

Document History:

- 08/16/2019 – Annual Review: Add may not approve criteria for combination use with other agents for amyloidosis. Wording and formatting changes. Coding Reviewed: Delete HCPCS code C9399, J3490 (Effective 10/1/19), Added HCPCS code J0222 (Effective 10/1/19) Added ICD-10 codes G62.9 and extended Code range E85.1-E85.9 to include TTR mutation.
- 12/4/2018 – HCPCS and ICD-10 Coding Review: Add HCPCS C9399 and ICD-10 E85.1.
- 10/9/2018 – Select Review: Add clinical criteria and quantity limit for Tegsedi following FDA approval.

- 08/17/2018 – Annual Review: Review preliminary clinical criteria for inotersen.

References

1. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis.* 2013;8(31).
2. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med.* 2018;379(1):22-31.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 3, 2019.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. *J Am Coll Cardiol.* 2015;66(21):2451-2466.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association